1. Home
  2. NTRA vs PODD Comparison

NTRA vs PODD Comparison

Compare NTRA & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$229.36

Market Cap

27.0B

Sector

Health Care

ML Signal

HOLD

Logo Insulet Corporation

PODD

Insulet Corporation

HOLD

Current Price

$284.56

Market Cap

22.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTRA
PODD
Founded
2003
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.0B
22.1B
IPO Year
2015
2007

Fundamental Metrics

Financial Performance
Metric
NTRA
PODD
Price
$229.36
$284.56
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
19
Target Price
$238.20
$366.58
AVG Volume (30 Days)
1.2M
677.7K
Earning Date
11-06-2025
02-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
3.45
Revenue
$2,116,676,000.00
$2,521,800,000.00
Revenue This Year
$33.18
$32.55
Revenue Next Year
$16.81
$20.50
P/E Ratio
N/A
$83.18
Revenue Growth
38.17
27.11
52 Week Low
$125.38
$230.05
52 Week High
$246.90
$354.88

Technical Indicators

Market Signals
Indicator
NTRA
PODD
Relative Strength Index (RSI) 52.01 34.82
Support Level $227.89 $285.02
Resistance Level $237.04 $290.60
Average True Range (ATR) 5.07 5.58
MACD -1.57 0.15
Stochastic Oscillator 49.47 0.00

Price Performance

Historical Comparison
NTRA
PODD

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

About PODD Insulet Corporation

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.

Share on Social Networks: